Quintrigen
Targeted Anti-cancer and Tumor Suppressor Drug
Company Overview
Snapshot
Founded in May 2019 by Orna Palgi and Anat Nursella, Quintrigen operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a p53-targeted anti-cancer and tumor suppressor drug. In October 2019, Quintrigen formed a joint venture between South Korea's Bioleaders and Israel's Weizmann Institute to advance p53-targeted research and development.
Business overview
Quintrigen is a Health Tech & Life Sciences company focused on the development of a targeted anti-cancer and tumor suppressor drug, p53. The company's core technology involves identifying small peptides capable of reactivating mutant p53 proteins, restoring their natural function to induce cancer cell death while sparing normal cells. Quintrigen operates within the Pharmaceuticals sector, specifically in drug discovery and development, serving the healthcare and life sciences markets.
Strategic signal
In October 2019, Quintrigen established a joint venture with South Korea's Bioleaders and Israel's Weizmann Institute to accelerate p53-targeted research and development. This collaboration signals a strategic move to leverage international expertise and resources in advancing its anti-cancer drug candidate, indicating a commitment to rigorous scientific validation and a potential pathway for future clinical development in the pharmaceutical industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Quintrigen's primary focus?
- Quintrigen is focused on developing p53, a targeted anti-cancer and tumor suppressor drug that reactivates mutant p53 proteins to induce cancer cell death.
- When was Quintrigen founded and by whom?
- Quintrigen was founded in May 2019 by Orna Palgi and Anat Nursella.
- What was a key strategic development for Quintrigen in 2019?
- In October 2019, Quintrigen formed a joint venture with South Korea's Bioleaders and Israel's Weizmann Institute to advance p53-targeted research and development.
- What is the current status of Quintrigen?
- Quintrigen is currently Non Active, having ceased to operate in July 2025.
- What is Quintrigen's employee count?
- Quintrigen operates with 1–10 employees.